Cibus
CBUS

$9.85

1.2%

Market Cap: 226M

About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Employees: 183

Materials Agricultural Chemicals

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

0

News positive %

of 29 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

41% more funds holding

Funds holding: 34 [Q4 2023] → 48 (+14) [Q1 2024]

25% more capital invested

Capital invested by funds: $112M [Q4 2023] → $139M (+$27.4M) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

0.78% less ownership

Funds ownership: 30.3% [Q4 2023] → 29.51% (-0.78%) [Q1 2024]

58% less call options, than puts

Call options by funds: $370K | Put options by funds: $875K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$22

123%

upside

Avg. target

$24

144%

upside

High target

$25

154%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity Austin Moeller	123%upside $22	Buy Assumed	19 Jul 2024
HC Wainwright & Co. Amit Dayal	154%upside $25	Buy Reiterated	10 May 2024
HC Wainwright & Co. Amit Dayal	154%upside $25	Buy Maintained	22 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 29 articles about CBUS published over the past 30 days

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

Levi & Korsinsky Reminds Cibus, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CBUS

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

Levi & Korsinsky Reminds Cibus, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CBUS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

ATTENTION Cibus, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

ATTENTION Cibus, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ:CBUS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

CBUS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cibus, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

CBUS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cibus, Inc. Shareholders Who Lost Money

Levi & Korsinsky Announces an Investigation on Behalf of Cibus, Inc. (CBUS) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

Levi & Korsinsky Announces an Investigation on Behalf of Cibus, Inc. (CBUS) Shareholders Who May Have Been Affected by Fraud

An Investigation Has Commenced on Behalf of Cibus, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CBUS Losses.

NEW YORK, NY / ACCESSWIRE / July 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

An Investigation Has Commenced on Behalf of Cibus, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CBUS Losses.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS

Shareholder Rights Advocates at Levi & Korsinsky Investigate Cibus, Inc. (CBUS) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Cibus, Inc. (CBUS) Regarding Possible Securities Fraud Violations

See News Rankings